MedKoo Cat#: 596540 | Name: L 377202

Description:

WARNING: This product is for research use only, not for human or veterinary use.

L 377202 is a peptide-doxorubicin conjugate activated by prostate-specific antigen.

Chemical Structure

L 377202
L 377202
CAS#207395-85-5

Theoretical Analysis

MedKoo Cat#: 596540

Name: L 377202

CAS#: 207395-85-5

Chemical Formula: C65H89N9O25

Exact Mass: 1395.5970

Molecular Weight: 1396.46

Elemental Analysis: C, 55.91; H, 6.42; N, 9.03; O, 28.64

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
L 377202; L-377202; L377202; L-377,202; L 377,202; L377,202;
IUPAC/Chemical Name
5-((2S)-2-(((2S,5S,8S,11S,14S,17S)-11-(3-amino-3-oxopropyl)-8-cyclohexyl-17-(((2S,3S,4S,6R)-3-hydroxy-2-methyl-6-(((1R,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl)oxy)tetrahydro-2H-pyran-4-yl)carbamoyl)-5,14-bis(hydroxymethyl)-19-methyl-3,6,9,12,15-pentaoxo-4,7,10,13,16-pentaazaicosan-2-yl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-5-oxopentanoic acid
InChi Key
CZXGBIFEWYVYJY-BBOLZPAQSA-N
InChi Code
InChI=1S/C65H89N9O25/c1-28(2)19-37(60(91)69-36-21-47(98-30(4)53(36)84)99-42-23-65(96,43(79)27-77)22-34-49(42)57(88)51-50(55(34)86)54(85)33-13-9-14-41(97-5)48(33)56(51)87)70-61(92)38(25-75)72-59(90)35(17-18-44(66)80)68-64(95)52(31-11-7-6-8-12-31)73-62(93)39(26-76)71-58(89)29(3)67-63(94)40-20-32(78)24-74(40)45(81)15-10-16-46(82)83/h9,13-14,28-32,35-40,42,47,52-53,75-78,84,86,88,96H,6-8,10-12,15-27H2,1-5H3,(H2,66,80)(H,67,94)(H,68,95)(H,69,91)(H,70,92)(H,71,89)(H,72,90)(H,73,93)(H,82,83)/t29-,30-,32?,35-,36-,37-,38-,39-,40-,42+,47-,52-,53+,65-/m0/s1
SMILES Code
O=C(c1c(OC)cccc12)c3c(O)c4c(C[C@](C(CO)=O)(O)C[C@H]4O[C@H]5C[C@@H]([C@H](O)[C@H](C)O5)NC([C@H](CC(C)C)NC([C@H](CO)NC([C@H](CCC(N)=O)NC([C@H](C6CCCCC6)NC([C@H](CO)NC([C@H](C)NC([C@H]7N(CC(O)C7)C(CCCC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)c(O)c3C2=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,396.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: DiPaola RS, Rinehart J, Nemunaitis J, Ebbinghaus S, Rubin E, Capanna T, Ciardella M, Doyle-Lindrud S, Goodwin S, Fontaine M, Adams N, Williams A, Schwartz M, Winchell G, Wickersham K, Deutsch P, Yao SL. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J Clin Oncol. 2002 Apr 1;20(7):1874-9. PubMed PMID: 11919247. 2: DeFeo-Jones D, Garsky VM, Wong BK, Feng DM, Bolyar T, Haskell K, Kiefer DM, Leander K, McAvoy E, Lumma P, Wai J, Senderak ET, Motzel SL, Keenan K, Van Zwieten M, Lin JH, Freidinger R, Huff J, Oliff A, Jones RE. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat Med. 2000 Nov;6(11):1248-52. PubMed PMID: 11062536.